Anticoagulant News and Research

RSS
Study examines mental health prognosis of young VTE patients

Study examines mental health prognosis of young VTE patients

Expert report highlights urgent action needed to lessen the future impact of Atrial Fibrillation in Europe

Expert report highlights urgent action needed to lessen the future impact of Atrial Fibrillation in Europe

Researchers develop hybrid tissue-engineered heart valve using patient's own cells

Researchers develop hybrid tissue-engineered heart valve using patient's own cells

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes  in CLL/SLL patients

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Study suggests race-specific equations to aid clinicians better calculate warfarin dosage

Study suggests race-specific equations to aid clinicians better calculate warfarin dosage

Newer anticoagulant medication may increase risk of GI bleeding in older patients

Newer anticoagulant medication may increase risk of GI bleeding in older patients

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

COPD associated with increased mortality in patients with atrial fibrillation, but not stroke

COPD associated with increased mortality in patients with atrial fibrillation, but not stroke

Blood-thinning treatment safe for patients with brain metastases

Blood-thinning treatment safe for patients with brain metastases

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Study looks at dabigatran adherence across Veterans Health Administration sites

Study looks at dabigatran adherence across Veterans Health Administration sites

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Northwestern University researchers find safer way to improve surgery outcomes

Northwestern University researchers find safer way to improve surgery outcomes

New article highlights need for optimization of warfarin therapy

New article highlights need for optimization of warfarin therapy

Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

New study pinpoints major increase in subdural hematoma surgery by 2030

New study pinpoints major increase in subdural hematoma surgery by 2030

Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.